Connect with us

Uncategorized

VEXT SCIENCE Receives Approval from City of Phoenix for Expansion of Cultivation, Extraction and Production Footprints

Vext Science, Inc. (OTCQX: VEXTF) (CSE: VEXT) a cannabinoid brand leader leveraging core expertise in extraction, manufacturing, cultivation and marketing to build wholesale distribution through revenue and joint ventures, today announced that it has obtained approval from the City of Phoenix to begin a 10,000 square foot expansion at its Phoenix location. The expansion will […]

The post VEXT SCIENCE Receives Approval from City of Phoenix for Expansion of Cultivation, Extraction and Production Footprints appeared first on Technical420.

Republished by Plato

Published

on

Vext Science, Inc. (OTCQX: VEXTF) (CSE: VEXT) a cannabinoid brand leader leveraging core expertise in extraction, manufacturing, cultivation and marketing to build wholesale distribution through revenue and joint ventures, today announced that it has obtained approval from the City of Phoenix to begin a 10,000 square foot expansion at its Phoenix location. The expansion will be comprised of additional cultivation capacity, a new lab, and expansions in the kitchen and finished goods processing areas. The Company expects to begin construction in September, with targeted completion in the first quarter.

Vext Science, Inc. logo (CNW Group/Vext Science, Inc.)

Management Commentary

“With our second Herbal Wellness Center dispensary location in Phoenix open as of July 10, 2020, and the expectation of significant growth in demand should Arizona move to an adult-use market in 2021, this expansion will ensure we are ready to both supply our own needs as well as to take advantage of profitable wholesale and white label opportunities as the market grows,” said Eric Offenberger, CEO of VEXT. “This expansion is directly aligned with our value-added strategy of managing high volume dispensary locations, while growing cultivation capacity and state of the art managed extraction and kitchen facilities to support them. Arizona is our home market and we couldn’t be more excited to continue serving our valued patients at our two Phoenix Herbal Wellness Center locations, while preparing to open the doors to a whole new range of consumers in 2021. VEXT is well-positioned to continue growing profitably in Arizona, with a successful track record of disciplined execution, and a steady focus on generating solid returns on capital and profitability for shareholders.”

About VEXT Science, Inc.

Vext Science, Inc. is a US-based Cannabis THC and Hemp cannabinoid products company manufacturing THC cartridges, concentrates, edibles and accessories under the Vapen™ Brand, and Hemp based products under the Pure Touch Botanicals brand as well as the Vapen CBD brand. Based in Arizona, Vext Science, Inc. has one of the leading THC concentrates, edibles, and distillate cartridge brands sold in most of the state’s 100+ dispensaries. Herbal Wellness Center is one of Arizona’s leading dispensaries and we execute all aspects of the cultivation, extraction, edibles infusion and manufacturing processes which insures a product of the highest quality and purity. Product quality and purity are core to our marketing strategy. Vext Science, Inc. is executing its business growth by leveraging experience and expertise in extractions, product manufacturing, and marketing to expand in the U.S. and internationally through revenue and profit-sharing joint venture partnerships. For more information visit our website at www.VextScience.com.

COVID-19 Risk Factor

VEXT may be impacted by business interruptions resulting from pandemics and public health emergencies, including those related to COVID-19. An outbreak of infectious disease, a pandemic, or a similar public health threat, such as the recent outbreak of COVID-19, or a fear of any of the foregoing, could adversely impact VEXT by causing operating, manufacturing, supply chain, and project development delays and disruptions, labor shortages, travel, and shipping disruption and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how VEXT may be affected if such a pandemic persists for an extended period of time, including as a result of the waiver of regulatory requirements or the implementation of emergency regulations to which VEXT is subject. Although VEXT has been deemed essential and/or has been permitted to continue operating its facilities in the states in which it operates during the pendency of the COVID-19 pandemic, there is no assurance that the Company’s operations will continue to be deemed essential and/or will continue to be permitted to operate. VEXT may incur expenses or delays relating to such events outside of its control, which could have a material adverse impact on its business, operating results, financial condition and the trading price of the Company’s Common Shares.

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in VEXT’s periodic filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward- looking statements.

Forward-looking statements may include, without limitation, statements related COVID-19, to future developments and the business and operations of VEXT, the proposed operational timeline for the joint venture with Texoma and the Processing Facility, and revenue and profit contribution for VEXT’s operations.

Although VEXT has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; being engaged in activities currently considered illegal under U.S. Federal laws; change in laws; reliance on management; requirements for additional financing; competition; hindered market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. Because of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward- looking statements in this news release are made as of the date of this release. VEXT disclaims any intention or obligation to update or revise such information, except as required by applicable law, and VEXT does not assume any liability for disclosure relating to any other company mentioned herein.

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Eric Offenberger
Chief Executive Officer

SOURCE Vext Science, Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/August2020/18/c6151.html

Brian Cameron, Vext Science, Inc., brian@vextscience.com , 602-865-9356Copyright CNW Group 2020

Source: https://technical420.com/cannabis-article/vext-science-receives-approval-from-city-of-phoenix-for-expansion-of-cultivation-extraction-and-production-footprints/

Uncategorized

Medipharm Labs Is Trading At A Steep Discount To Its Peers Despite Transformational Changes Across Several Key Business Units

A few weeks ago, we issued an update on MediPharm Labs Corporation (LABS.TO) (MEDIF) after it expanded its presence on the international side of the industry. Through strategic agreements with leading operators in the European Union (EU) and South America, the company has significantly enhanced its growth prospects. Despite the positive developments that were reported […]

The post Medipharm Labs Is Trading At A Steep Discount To Its Peers Despite Transformational Changes Across Several Key Business Units appeared first on Technical420.

Republished by Plato

Published

on

A few weeks ago, we issued an update on MediPharm Labs Corporation (LABS.TO) (MEDIF) after it expanded its presence on the international side of the industry. Through strategic agreements with leading operators in the European Union (EU) and South America, the company has significantly enhanced its growth prospects.

Despite the positive developments that were reported by MediPharm, we believe that the market substantially discounts the upside that is associated with the business in Canada and abroad.

When compared to Neptune Wellness Solutions Inc. (NEPT.TO) (NEPT), MediPharm is valued at less than half of Neptune (from a market capitalization standpoint as of October 15, 2020). We find the valuation disparity to be worth highlighting and believe that MediPharm has a favorable risk-reward profile as a result.

Executing on a Multi-National Growth Strategy

2020 has been a challenging year for the global economy and many companies pivoted the business model to be levered to the opportunities that were created by the COVID pandemic. During the crisis, Neptune entered the hand sanitizer business and started selling products across Canada.

When Neptune reported this development, the market responded extremely positive to the announcement. Since then, the shares have pulled back and we believe that the change of focus benefited MediPharm. By taking the full focus of the cannabis concentrate market, MediPharm was able to benefit and capitalize on its competitor’s change of model.

While Neptune was off making hand sanitizer, MediPharm was executing on a multi-national growth strategy. Currently, MediPharm has more than 30 tolling and processing agreements with operators in 8 countries. When compared to its peers, we believe that the company has more attractive growth prospects in Canada and abroad.

Although MediPharm has substantial domestic and international growth prospects, we believe the market is discounting this aspect of the story. In the first half of 2021, MediPharm expects to see international revenue growth ramp higher which should result in substantial margin expansion. In the EU, the price of cannabis products is incrementally higher than Canada and this is an attractive aspect of the international market.

Going forward, we believe that MediPharm will continue to take market share from companies like Neptune. The company operates a state-of-the-art GMP facility that allows them to capitalize on international markets while it continues to service the Canadian medical and recreational market.

During the last quarter, we have noticed a substantial increase in the amount of cannabis 2.0 products that are being sold in Canada. To create these products, licensed producers need access to cannabis oil, and this is where MediPharm comes into play. The leading Canadian cannabis oil company has formed strategic relationships with leading brands and operators and are bullish on this aspect of the story.

A Business that is Reaching a Key Inflection Point

We believe that MediPharm is in the beginning of a major transformation that will result in the business being more a junior pharmaceutical company. The agreement that MediPharm recently entered into with STADA puts the business in a league of its own and we are favorable on the potential avenues that it will have for growth.

In our opinion, MediPharm was miles ahead of its competition from the beginning. From the beginning, the management team understood that the best long-term opportunity would require that they have leverage to the global cannabis oil market. The Canadian market quickly became saturated and this made the economics of the business less attractive. MediPharm invested in the construction of a state-of-the-art processing facility that meets EU GMP standards to capitalize on the global market and this is an important pillar of the business.

One of MediPharm’s largest clients is Canopy Growth Corporation (WEED.TO) (CGC). Since inception, the management team focused on working and partnering with companies that are considered to be leaders in their respective industries. This stands true for the relationship that MediPharm has with STADA and we are bullish on the growth prospects that are associated with it.

Currently, STADA is a leader in its field and has approx. 20% of market share of the generic pharmaceutical industry in EU and Germany. We expect the relationship to play a key role in how MediPharm is able to capture market share and believe that the market discounts the potential that is associated with this opportunity.

Trading at a Discount on Several Metrics

From a valuation perspective, we believe that MediPharm represents a compelling opportunity. We are of the opinion that the Canadian cannabis oil company is trading at a discount when measured by profitability metrics, comparative analysis, and a forward-looking view of the business.

Over the next year, we expect MediPharm to report margin expansion as it continues to cut costs and ramp revenues. Once the international side of the business starts to ramp up, we expect the market to take notice. At this time, we are of the opinion that MediPharm will have laid the necessary infrastructure in key jurisdictions through its relationship with STADA. We believe the management team is bringing the business down a path to profitability and consider the opportunity to be underappreciated at current levels.

On top of the potential that is associated with the international opportunity, MediPharm is capitalizing on Canada’s cannabis 2.0 market. This market includes vape pens, edibles, topicals, beverages, concentrates, and more. To make these products, companies need access to cannabis oil. MediPharm makes the key input product that these operators and brands need and is positioned to be a major beneficiary of Canada’s 2.0 market.

Currently, MediPharm is making more than 60 products that are on the 2.0 market and we believe that the market does not fully understand the size and scope of the business. We consider MediPharm to be an undervalued opportunity that is focused on the pharmaceutical side of the industry. The company has a strong balance sheet and will be generating significant cash flow to support this side of the business. Going forward, we believe that MediPharm is well positioned to execute on several major growth projects and is an opportunity that we are excited about.

If you are interested in learning why we believe MediPharm Labs is positioned to take market share in Canada and abroad from companies like Neptune, please send an email to support@technical420.com with the subject “MediPharm” to be added to our distribution list.

Pursuant to an agreement between StoneBridge Partners LLC and Medipharm Labs we have been hired for a period of 180 days beginning August 18, 2020 and ending March 18, 2020 to publicly disseminate information about (LABS) including on the Website and other media including Facebook and Twitter. We are being paid $6,000 per month (LABS) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero (0) shares of (LABS), which we purchased in the open market. We plan to sell the “ZERO” shares of (LABS) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (LABS) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Share Share - Facebook Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Source: https://technical420.com/cannabis-article/medipharm-labs-is-trading-at-a-steep-discount-to-its-peers-despite-transformational-changes-across-several-key-business-units/

Continue Reading

Uncategorized

Lexaria Bioscience Granted First European Patent for DehydraTECH Technology

Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in oral drug delivery platforms, is pleased to announce that it is receiving its first-ever granted patent in Europe related to its DehydraTECHTM technology. European patent number 3164141 will be published in the European Patent Bulletin of November 11, 2020 entitled “Food and Beverage Compositions […]

The post Lexaria Bioscience Granted First European Patent for DehydraTECH Technology appeared first on Technical420.

Republished by Plato

Published

on

Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in oral drug delivery platforms, is pleased to announce that it is receiving its first-ever granted patent in Europe related to its DehydraTECHTM technology.

European patent number 3164141 will be published in the European Patent Bulletin of November 11, 2020 entitled “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof” and includes claims for improved oral delivery of cannabinoids, nicotine, non-steroidal anti-inflammatory drugs (NSAIDs) and vitamins.

– ADVERTISEMENT –

In addition, this patent includes important method of treatment claims for a broad range of disease conditions including use of:

  • cannabinoids to treat cardiac conditions such as hypertension and neurological diseases such as Alzheimer’s and Parkinson’s;
  • cannabinoids to treat metabolic disorders and substance abuse and addictions;
  • nicotine to treat tobacco dependence/addiction and neurological diseases;
  • NSAIDs to treat a host of conditions involving pain, fever and inflammatory states; and,
  • vitamins to treat conditions such as ataxia related to certain vitamin deficiencies.

Priority is granted to certain dates in 2014 and 2015, strengthening Lexaria’s IP claims compared to more recent competitors. This represents the first patent issuance in Europe under Lexaria’s first patent family.

Lexaria intends to validate and nationalize this patent in many major European countries, significantly expanding our global reach. This patent is a significant addition to the Lexaria intellectual property portfolio, and toward Lexaria’s first formal patent protection across major European nations covering a population of roughly 340 million people.

“We’re very pleased to be awarded our very first European patent grant as we’re continually working to expand both the geography where Lexaria’s intellectual property is protected under law, as well as expand the scope of business possible,” said Chris Bunka, Lexaria Chief Executive Officer. “The receipt of this patent grant is timely in that we have recently forged new relationships in Europe where a number of countries have very progressive markets for the oral delivery of active substances including nicotine and more, supporting our commercialization efforts.”

Lexaria currently has 18 granted patents (including nine granted in the US), along with approximately 60 patent applications pending throughout the world. The granted patents cover delivery of cannabinoids, NSAIDs, nicotine and fat-soluble vitamins. Pending patents are for the delivery of many antiviral drugs, human hormones such as testosterone and estrogen, phosphodiesterase inhibitors and more.

About Lexaria

Lexaria Bioscience Corp.’s (OTCQX:LXRP)(CSE:LXX) proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH increases bio-absorption by up to 5-10x, reduces time of onset from 1 – 2 hours to minutes, and masks unwanted tastes for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine, and other molecules. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a federally licensed research laboratory and holds a robust intellectual property portfolio with 18 patents granted and approximately 60 patents pending worldwide. For more information, please visit www.lexariabioscience.com.

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, all statements by the company related to patents granted or pending. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company’s ability to maintain existing collaborations and realize the benefits thereof, and other factors which may be identified from time to time in the Company’s public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance the Company will be capable of developing, marketing, licensing, or selling products containing any active ingredient. There is no assurance that any planned corporate activity, scientific research or study, business venture, letter of intent, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful or defensible. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.

Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

INVESTOR CONTACT:

ir@lexariabioscience.com
Phone: 866-221-3341

SOURCE: Lexaria Bioscience Corp.

Share Share - Facebook Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Source: https://technical420.com/cannabis-article/lexaria-bioscience-granted-first-european-patent-for-dehydratech-technology/

Continue Reading

Uncategorized

Meta Growth Announces Strong Support and Board Nominees in Connection with Proposed Arrangement with High Tide

Meta Growth Corp. (TSXV: META) (“Meta Growth”, “META” or the “Company”) is pleased to announce that in connection with the previously announced proposed acquisition pursuant to which High Tide Inc. (“High Tide”) will acquire all of the issued and outstanding common shares of META (“META Shares”) by way of a plan of arrangement under the […]

The post Meta Growth Announces Strong Support and Board Nominees in Connection with Proposed Arrangement with High Tide appeared first on Technical420.

Republished by Plato

Published

on

Meta Growth Corp. (TSXV: META) (“Meta Growth”, “META” or the “Company”) is pleased to announce that in connection with the previously announced proposed acquisition pursuant to which High Tide Inc. (“High Tide”) will acquire all of the issued and outstanding common shares of META (“META Shares”) by way of a plan of arrangement under the Business Corporations Act ( Alberta ) (the “Arrangement”), it has received strong preliminary support from META shareholders for the Arrangement, including, as previously announced, voting support agreements entered into by certain directors, officers and significant shareholders that collectively hold 14.1% of the outstanding META Shares. In addition, META is pleased to announce that Michael Cosic and Christian Sinclair will act as META’s nominees to the board of directors of High Tide (the “High Tide Board”) upon closing of the Arrangement, subject to receipt of all necessary regulatory approvals.

Meta Growth Corp. (CNW Group/Meta Growth Corp.)

As an update to the disclosure provided in the management information circular (the “Information Circular”) for the special meeting of holders of META Shares to be held on October 27, 2020 (the “Meeting”), Michael Cosic replaces Chris Brawn as one of META’s board nominees. Mr. Brawn has decided not to proceed as one of META’s board nominees for personal reasons but is expected to continue as an advisor to the High Tide Board upon closing of the Arrangement. As META’s current Chief Financial Officer, Mr. Cosic’s appointment is expected to provide continuity to the combined company through his ability to assist in post-closing transition and integration matters.

It is expected that, subject to receipt of all regulatory, court, shareholder and other approvals, the Arrangement will be completed in the fourth quarter of 2020.

Voting and Participation

Amid ongoing concerns about the Coronavirus (COVID-19) outbreak, META remains mindful of the well-being of its shareholders and their families, its industry partners and other stakeholders as well as the communities in which META operates. Accordingly, META will hold the Meeting virtually via live audio webcast, available online using the LUMI meeting platform at https://web.lumiagm.com/232399830 , on Tuesday, October 27, 2020 at 11:00 a.m. (EST). Holders of META Shares (“META Shareholders”) will not be able to attend the Meeting in person. A summary of the information META Shareholders will need to attend the Meeting online is provided in the Information Circular.

Your vote is important regardless of the number of META Shares you own. All META Shareholders are encouraged to vote their proxies before 11:00 a.m. (EST) onOctober 23, 2020 .

For META Shareholders with Questions or Requiring Assistance Voting

If you have any questions regarding the submission of your proxy, please contact Kingsdale Advisors, the strategic advisor and the proxy solicitation agent for META, by telephone at 1-800-749-9052 toll-free in North America (+1-416-867-2272 collect) or by e-mail at contactus@kingsdaleadvisors.com .

About Meta Growth

Meta Growth is a leader in secure, safe and responsible access to legal recreational cannabis in Canada . Through its Canada -wide network of Meta Cannabis Co.™, Meta Cannabis Supply Co.™ and NewLeaf Cannabis™ recreational cannabis retail stores, Meta Growth enables the public to gain knowledgeable access toCanada’s network of authorized Licensed Producers of cannabis. Meta Growth is listed on the TSX Venture Exchange under the symbol (TSXV: META).

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements

Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements with respect to META’s board nominees to the High Tide Board and the appointment of a High Tide board advisor, the anticipated timing for the Meeting and closing of the Arrangement, and the satisfaction of closing conditions for the Arrangement including, without limitation: (i) required META Shareholder approval; (ii) necessary court approval in connection with the Arrangement, (iii) High Tide obtaining the necessary approvals from the Canadian Securities Exchange for the delisting of securities, and the necessary approvals from the TSX Venture Exchange for the listing of securities in connection with the Arrangement; (iv) the Company obtaining the necessary approvals from the TSX Venture Exchange for the delisting of the META Shares; and (v) other closing conditions, including, without limitation, obtaining certain consents and the operation and performance of the High Tide and the Company businesses in the ordinary course until closing of the Arrangement. In particular, there can be no assurance that the Arrangement will be completed.

Forward-looking statements are based on current expectations, estimates, projections, and assumptions of the Company and High Tide described herein including, without limitation, expected growth, results of operations, performance and industry trends. While the Company considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements also necessarily involve known and unknown risks, including, without limitation, risks associated with the delay or failure to receive regulatory approvals with respect to the Arrangement or the Arrangement not proceeding. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof, and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Factors that could cause anticipated opportunities and actual results to differ materially include, but are not limited to, matters referred to above and elsewhere in the Company’s and High Tide’s public filings.

SOURCE Meta Growth Corp.

Source: https://technical420.com/cannabis-article/meta-growth-announces-strong-support-and-board-nominees-in-connection-with-proposed-arrangement-with-high-tide/

Continue Reading
Heartland22 hours ago

Web site credit card processing

Heartland9 hours ago

CBG Study Shows Antimicrobial Properties of Cannabis

Heartland4 days ago

CBD Flower vs Vaping

Heartland4 days ago

CBD weed in the U.K.

Heartland3 days ago

Best cbd oil uk

Heartland4 days ago

Is your child texting about CBD?

Heartland4 days ago

Giveaway for CBD Gummies on Instagram

Heartland5 days ago

Plant more hemp trees

Heartland4 days ago

How effective is Charlotte’s Web for epilepsy

Heartland4 days ago

The Divine Root

Heartland4 days ago

A similar thing to this, but for CBD?

Material4 days ago

Constitutive relationships of 21-4 N heat-resistant steel for the hot forging process

Material4 days ago

High-temperature deformation behavior and microstructural evolution of as-cast and hot rolled β21S alloy during hot deformation

Heartland3 days ago

Interesting effects from full spectrum

Heartland3 days ago

Anyone else find Dosist pens wonky?

Heartland3 days ago

What type of hemp products do you use?

Heartland4 days ago

Oof- CBD flower experience gone bad..

Heartland4 days ago

Has anyone ever tired any products from, “theremedy.care”? Wanting to try the CBD:CBG vape.

Heartland3 days ago

Awful taste – Lazarus Naturals. Is there flavored version better ?

Heartland3 days ago

ICE HEADSHOP.co.uk

Heartland2 days ago

CBG tinctures

CBD5 days ago

A88CBD: The Alkaline 88 Family Review

CBD5 days ago

CBD News Roundup: HIA & RE Botanicals Partner To Block DEA Ruling On Hemp Extracts

Heartland5 days ago

How to Get Medical Marijuana Card Application in Florida in 4 Simple Steps

CBD4 days ago

Receptra CBD Oil Review

Heartland4 days ago

Amazon Begins Selling CBD Products Within The United Kingdom

Heartland3 days ago

The Hemp Store Strategizes Wholesale Agreement With Maine Coast Hemp

CBD2 days ago

CBD and Geriatric Medicine: Should Seniors Take CBD?

Heartland3 days ago

Making cbd/cbg tinture

Heartland5 days ago

It’s working for anxiety but is the amount I’m using too much?

Trending

A Cloud Nine Capital Entity Copyright © 2020 – All Rights Reserved Proudly Made in America